PIM1
Overview
PIM1 encodes a serine/threonine kinase with roles in cell survival, proliferation, and differentiation. In B-cell lymphomas, PIM1 is a known target of aberrant somatic hypermutation (SHM) mediated by activation-induced cytidine deaminase (AID), accumulating mutations at WRCY AID target motifs. PIM1 is among the most recurrently mutated genes in DLBCL.
Alterations observed in the corpus
- PIM1 harbored 22 somatic mutations in 15 of 55 DLBCL patients (whole-exome sequencing, Broad cohort); mutations were enriched in WRCY AID target motifs, confirming aberrant somatic hypermutation as the mutational mechanism PMID:22343534
- In primary central nervous system lymphoma (PCNSL), PIM1 mutations occur in 40% of cases, among the most frequently mutated genes alongside CD79B and MYD88, all within the BCR/TLR/NF-κB pathway altered in >90% of PCNSL. PMID:25991819
- PIM1 preferentially mutated in ABC DLBCL in a 1001-patient genomic cohort PMID:28985567
Cancer types (linked)
- DLBCL: among the top significantly mutated genes by MutSig (q ≤ 0.1); 15/55 (27%) patients mutated PMID:22343534
Co-occurrence and mutual exclusivity
- Co-mutated with BCL2 in the aberrant somatic hypermutation context in DLBCL PMID:22343534
Therapeutic relevance
- PIM1 kinase is a candidate therapeutic target in DLBCL; multiple PIM kinase inhibitors are in development, though none were directly evaluated in the cited corpus study PMID:22343534
Open questions
- Whether PIM1 mutations in DLBCL are functional drivers or AID-mediated passenger events co-occurring with BCL2/IgH translocation remains an open question PMID:22343534
Sources
This page was processed by crosslinker on 2026-05-14. - PMID:25991819
This page was processed by crosslinker on 2026-05-14. - PMID:28985567
This page was processed by wiki-cli on 2026-05-15.